G1 Therapeutics

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

G1 Therapeutics excels in Q4 with Cosela sales surge and optimistic 2023 outlook

G1 Therapeutics delivered strong financial results in Q4 2022, driven by the impressive performance of Cosela in the small cell lung cancer market. Despite organizational changes to conserve capital, the company remains focused on growth and innovation. With a solid cash balance projection for 2023 and a growing customer base, G1 Therapeutics is poised for continued success.

G1 Therapeutics reports robust Q1 performance and optimistic growth outlook

G1 Therapeutics demonstrated strong financial performance and commercial growth in Q1 2023, with COSELA showing promising results and a positive outlook for the future.
While facing challenges related to potential drug interactions, the company is well-positioned to capitalize on opportunities through upcoming data readouts and strategic decisions.
Investors can be optimistic about G1 Therapeutics' continued progress, supported by a solid financial foundation and a focus on maximizing COSELA's potential.

G1 Therapeutics reports resilient Q2 performance amidst challenges and opportunities

G1 Therapeutics delivered a strong financial performance in Q2 2023, showcasing resilience and strategic financial management amidst challenges.
The company's focus on advancing its clinical pipeline and securing survival results in early 2024 positions it for future growth and value creation.
While facing challenges such as a chemotherapy shortage and operational efficiency, G1 Therapeutics maintains stability and confidence in its financial outlook.
Opportunities lie in capitalizing on COSELA sales growth, advancing clinical programs, and leveraging financial flexibility for sustained growth and innovation.

G1 Therapeutics overcomes supply challenges, eyes growth in oncology

G1 Therapeutics exhibited resilience in revenue growth despite challenges with COSELA's market supply, showcasing operational strength.
The company's strong financial position and cost management efforts bode well for sustainable growth and value creation.
Exciting opportunities in clinical trials and market expansion present avenues for future success and competitive positioning in the oncology sector.

G1 Therapeutics excels in Q4 2023, poised for growth ahead

G1 Therapeutics demonstrated strong performance in Q4 2023 with notable revenue growth and expense management.
COSELA's market share and promising trial results highlight strengths in the product portfolio.
While challenges like trial result anticipation and cost efficiency persist, opportunities for growth and optimization are evident.
Overall, G1 Therapeutics shows promise with a healthy cash position and positive sales guidance for 2024.

G1 Therapeutics reports strong Q1 earnings and diversifies revenue streams

G1 Therapeutics delivered robust financial results, showcasing growth in revenue and cost management improvements in Q1 2024.
While facing challenges in managing expenses and advancing clinical trials, the company remains optimistic about revenue guidance and market opportunities.
With a solid cash position and strategic partnerships, G1 Therapeutics is well-positioned to drive future growth and innovation in the oncology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.

Effective Today, New J-code to Streamline Reimbursement Effective Today, New J-code to Streamline Reimbursement

G1 Therapeutics Announces Permanent J-Code from Centers for Medicare and Medicaid Services

- New G1 Sales Force to Focus on Top Tier Accounts to Accelerate Sales Activities - - New G1 Sales Force to Focus on Top Tier Accounts to Accelerate Sales Activities -

G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force

RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in September.

G1 Therapeutics to Participate in Two Upcoming September Conferences

G1 Therapeutics is now a commercialization-stage operator having a potential mega-blockbuster (Cosela). Cosela is filling a heightened demand to treat myelosuppression associated with chemotherapy.

G1 Therapeutics: Poised To Deliver A Blockbuster

GTHX is down considerably from its February highs. Recently approved Cosela is starting out well.

G1 Therapeutics: Pullback Presents Opportunity

The heavy selling pressure might have exhausted for G1 THERAPEUTICS (GTHX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here's Why G1 THERAPEUTICS (GTHX) is Poised for a Turnaround After Losing 16.4% in 4 Weeks

G1 Therapeutics, Inc. (GTHX) CEO John Bailey on Q2 2021 Results - Earnings Call Transcript

G1 THERAPEUTICS (GTHX) delivered earnings and revenue surprises of 2.08% and 144.77%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

G1 THERAPEUTICS (GTHX) Reports Q2 Loss, Tops Revenue Estimates

- Achieved $6.6 Million in Total Revenue, including $2.5 Million in Net Revenue from Sales of COSELA™ (trilaciclib) -

G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights

Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Company Also Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

G1 Therapeutics Announces Appointment of Andrew Perry as Chief Commercial Officer

G1 THERAPEUTICS (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate G1 THERAPEUTICS (GTHX) to Report a Decline in Earnings: What to Look Out for

RESEARCH TRIANGLE PARK, N.C., July 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to COSELA™ (trilaciclib) investigation for use in combination with chemotherapy for the treatment of locally advanced or metastatic triple negative breast cancer (TNBC). COSELA is currently being evaluated in PRESERVE 2, a pivotal Phase 3, randomized, double-blind, placebo-controlled study (NCT04799249) in patients receiving first- or second-line gemcitabine and carboplatin chemotherapy for TNBC. (press release)

G1 Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA™ (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer

RESEARCH TRIANGLE PARK, N.C., June 18, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Alicia Secor to its Board of Directors. With more than 30 years of experience in the life sciences industry, she has a proven track record of leading life sciences businesses, guiding products from clinical development through approval and global commercialization, and enabling companies to optimize the potential of innovative brands. Ms. Secor currently serves as President and Chief Executive Officer of Atalanta Therapeutics, Inc., a privately held biotechnology company pioneering new treatment options for neurodegenerative diseases and is a member of its Board of Directors.

G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors

RESEARCH TRIANGLE PARK, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey will participate in the 2021 Raymond James Human Health Innovation Conference. The fireside chat will take place on June 22nd at 9:20 AM EDT. This meeting is being held virtually, and a live webcast will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

G1 Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference

G1 Therapeutics Inc (NASDAQ: GTHX) has initiated the PRESERVE 3 Phase 2 study evaluating Cosela (trilaciclib) in patients with untreated, locally advanced, or metastatic urothelial carcinoma (mUC). Cosela will be administered with first-line platinum-based chemotherapy and the immune checkpoint inhibitor avelumab maintenance therapy.

G1 Therapeutics Starts Mid-Stage Bladder Cancer Trial With Cosela

- Combination of Rintodestrant and Palbociclib was Very Well Tolerated with No Reported Discontinuations due to Treatment-Emergent Adverse Events (TEAEs) -

G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer

RESEARCH TRIANGLE PARK, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:  GTHX ), a commercial-stage oncology company, today presented results from analyses evaluating the immune effects of trilaciclib in patients with extensive-stage small cell lung cancer (ES-SCLC) following two Phase 2 clinical trials. Results of the analyses, presented at the American Society of Clinical Oncology (ASCO) annual virtual meeting, demonstrated that patients receiving COSELA prior to chemotherapy had greater peripheral T-cell clonal expansion than patients receiving placebo. The goal of clonal expansion is to amplify the number of specific lymphocytes (B-cells and T-cells) to enable the body to have sufficient numbers of antigen-specific lymphocytes to mount an effective immune response. The eAbstract is available in the scientific publications section of G1's website.

G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer

COSELA was approved in February after a good run-up. GTHX has multiple upcoming catalysts.

G1 Therapeutics: Depressed Price Post-Approval Presents Second Buying Opportunity

RESEARCH TRIANGLE PARK, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, being held virtually June 4th through 8th. The presentations will describe results from the Company's study of its oral selective estrogen receptor degrader (SERD), rintodestrant, in combination with palbociclib for the treatment of ER+/HER2- advanced breast cancer as well as data describing the effects of COSELA™ (trilaciclib) on T-cell activation and clonal expansion in patients with newly diagnosed extensive-stage small cell lung cancer. A copy of the posters will be made available on the G1 corporate website on June 4, 2021.

G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual Meeting

- A Cost-Benefit Model of Administration of COSELATM (trilaciclib) Prior to Chemotherapy Estimates Measurable Per-Patient Cost Savings -

G1 Therapeutics Presents Two Posters at ISPOR Describing the Estimated Economic Impact of Treating Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer

PRESERVE 4 Will Evaluate the Survival and Myeloprotection Benefits of COSELA in 146 Patients with Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Checkpoint Inhibitors PRESERVE 4 Will Evaluate the Survival and Myeloprotection Benefits of COSELA in 146 Patients with Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Checkpoint Inhibitors

G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA™ (trilaciclib) in Non-Small Cell Lung Cancer (PRESERVE 4)

The stock price of G1 Therapeutics Inc (NASDAQ: GTHX) increased 10.22% (from $19.77 to $21.79) pre-market. This is why it happened.

GTHX Stock: 10.22% Increase (From $19.77 To $21.79) Pre-Market Explanation

G1 Therapeutics, Inc. (GTHX) CEO Jack Bailey on Q1 2021 Results - Earnings Call Transcript

- G1's COSELA™ (trilaciclib), the Only FDA-Approved Proactive Multilineage Myeloprotection Therapy, Approved on February 12, 2021 and Commercially Available as of March 2, 2021 -

G1 Therapeutics Provides First Quarter 2021 Financial Results and Operational Highlights

RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2021 on Wednesday, May 5, 2021 at 4:30 p.m. ET.

News for G1 Therapeutics Stock (GTHX)